Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

KYMR Kymera Therapeutics Inc

Price (delayed)

$44.26

Market cap

$2.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.11

Enterprise value

$2.87B

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein ...

Highlights
KYMR's gross profit is down by 26% year-on-year but it is up by 25% since the previous quarter
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
The company's EPS fell by 24% YoY and by 4.4% QoQ

Key stats

What are the main financial stats of KYMR
Market
Shares outstanding
65.12M
Market cap
$2.88B
Enterprise value
$2.87B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.79
Earnings
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
EBIT
-$240.63M
EBITDA
-$232.67M
Free cash flow
-$239.96M
Per share
EPS
-$3.11
EPS diluted
-$3.11
Free cash flow per share
-$2.99
Book value per share
$12.11
Revenue per share
$0.73
TBVPS
$11.46
Balance sheet
Total assets
$918.31M
Total liabilities
$132.08M
Debt
$86.33M
Equity
$786.23M
Working capital
$441.96M
Liquidity
Debt to equity
0.11
Current ratio
8.49
Quick ratio
7.95
Net debt/EBITDA
0.04
Margins
EBITDA margin
-395.1%
Gross margin
100%
Net margin
-409.1%
Operating margin
-472.5%
Efficiency
Return on assets
-25.6%
Return on equity
-30.1%
Return on invested capital
-28%
Return on capital employed
-28%
Return on sales
-408.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
1.56%
1 week
53.68%
1 month
25.45%
1 year
38.57%
YTD
10.02%
QTD
61.71%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
Gross margin
100%
Net margin
-409.1%
The operating margin has plunged by 111% YoY but it has grown by 15% from the previous quarter
KYMR's net margin has dropped by 110% year-on-year but it is up by 14% since the previous quarter
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
The company's operating income has shrunk by 56% YoY and by 6% QoQ

Price vs fundamentals

How does KYMR's price correlate with its fundamentals

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
3.66
P/S
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.79
The company's EPS fell by 24% YoY and by 4.4% QoQ
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 2.8 but 15% less than its 5-year quarterly average of 4.3
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
The price to sales (P/S) is 84% higher than the 5-year quarterly average of 32.8 and 44% higher than the last 4 quarters average of 41.8
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter

Efficiency

How efficient is Kymera Therapeutics business performance
The company's return on sales has shrunk by 110% YoY but it rose by 14% QoQ
KYMR's return on assets is down by 7% year-on-year and by 6% since the previous quarter
The company's return on equity rose by 6% YoY but it fell by 4.9% QoQ
The return on invested capital has declined by 6% since the previous quarter and by 3.7% year-on-year

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
The total liabilities has contracted by 16% YoY and by 7% from the previous quarter
Kymera Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 9% QoQ
KYMR's debt is 89% smaller than its equity
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.